| Ulcerative Colitis
Zeposia vs Uceris
Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.Deep comparison between: Zeposia vs Uceris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUceris has a higher rate of injection site reactions vs Zeposia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uceris but not Zeposia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zeposia
Uceris
At A Glance
Oral
Once daily
S1P receptor modulator
Rectal foam
Twice daily, then once daily
Glucocorticosteroid
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Ulcerative Colitis
- Ulcerative Colitis
Dosing
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome, Ulcerative Colitis Initiate with 7-day titration (0.23 mg once daily days 1-4, 0.46 mg once daily days 5-7); maintenance dose 0.92 mg orally once daily starting day 8; patients with mild or moderate hepatic impairment (Child-Pugh class A or B) take 0.92 mg once every other day after titration.
Ulcerative Colitis 1 metered dose administered rectally twice daily for 2 weeks, followed by 1 metered dose administered rectally once daily for 4 weeks.
Contraindications
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure in the last 6 months
- Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
- Severe untreated sleep apnea
- Concurrent use of a monoamine oxidase (MAO) inhibitor
- History of known hypersensitivity to budesonide or any ingredient of UCERIS rectal foam, including anaphylaxis
Adverse Reactions
Most common (>=4%) Upper respiratory infection, hepatic transaminase elevation, orthostatic hypotension, urinary tract infection, back pain, hypertension (MS); liver test increased, upper respiratory infection, headache (UC)
Serious Infections, progressive multifocal leukoencephalopathy, bradyarrhythmia and AV conduction delays, liver injury, fetal risk, increased blood pressure, respiratory effects, macular edema, cutaneous malignancies, posterior reversible encephalopathy syndrome
Postmarketing Liver injury
Most common (>=2%) Decreased blood cortisol, adrenal insufficiency, nausea
Serious Hypercorticism and adrenal axis suppression, steroid withdrawal symptoms, increased susceptibility to infection, other glucocorticosteroid effects
Postmarketing Hypertension, pancreatitis, pyrexia, peripheral edema, anaphylactic reactions, dizziness, benign intracranial hypertension, mood swings, pruritus, maculopapular rash, allergic dermatitis
Pharmacology
Ozanimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in MS and ulcerative colitis is unknown but may involve reduced lymphocyte migration into the CNS and intestine.
Budesonide is a synthetic non-halogenated glucocorticosteroid that exerts local anti-inflammatory activity via glucocorticosteroid receptor binding; it undergoes extensive first-pass hepatic metabolism via CYP3A4, resulting in low systemic bioavailability.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zeposia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Uceris
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Zeposia
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (3/8)
Uceris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Zeposia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Uceris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Zeposia.
No savings programs available for Uceris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZeposiaView full Zeposia profile
UcerisView full Uceris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.